Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 24;22(1):1090.
doi: 10.1186/s12885-022-10167-5.

Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid

Sijian Li  1 , Xiaoxue Wang  1 , Xiaolong Sui  2 , Xinyue Zhang  1 , Min Yin  1 , Jiaxin Yang  3
Affiliations

Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid

Sijian Li et al. BMC Cancer. .

Abstract

Background: Ovarian strumal carcinoid is an extremely rare ovarian malignant tumor with limited data on clinical characteristics and survival outcomes.

Methods: A retrospective study of 119 patients was conducted, including 98 cases identified from literature review, and their clinical characteristics were investigated. The overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), and potential prognostic factors of these patients were also evaluated.

Results: Lesions of 115 cases were confined to the ovarian while four patients presented with extra-ovarian disease upon initial diagnosis. Surgical treatment options performed in this cohort varied, 5.0% received ovarian cystectomy, 36.1% received unilateral salpingo-oophorectomy (USO), 7.6% received bilateral salpingo-oophorectomy (BSO), 42.0% received hysterectomy with BSO, and 8.4% underwent debulking surgery. Moreover, one patient did not undergo any surgery. No postoperative adjuvant therapy was administered in 89.9% patients, while 7.6% and 2.5% received adjuvant radiotherapy and chemotherapy, of which two patients received combined radiation and chemotherapy. At the final follow-up, 89.1% patients showed no evidence of the disease, and 5.0% were alive with the disease. Only seven deaths occurred, with two attributed to the tumor. The 5-year, 10-year, and 20-year OS rates were 96.0%, 85.0%, and 85.0%, respectively, with a 15-year recurrence rate of 4.4%. The 5-year and 20-year DSS rate were 98.5% and 95.9%. Multivariate Cox regression showed age ≥ 55 years was the only risk factor associated with the OS (P = 0.014, OR 7.988; 95% CI 1.519 - 42.004). However, the univariate and multivariate Cox regression showed no potential risk factor for RFS and DSS.

Conclusion: Patients with ovarian strumal carcinoid have an excellent prognosis irrespective of the surgical option. Conservative surgery especially USO with individualized adjuvant therapy is recommended.

Keywords: Clinical characteristics; Ovarian carcinoid; Strumal carcinoid; Survival outcomes; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Pathological features of ovarian strumal carcinoid synchronous adenocarcinoma (yellow star, struma ovarii; red star, carcinoid component; blue star, adenocarcinoma component; case 17, HE staining, 200X)
Fig. 2
Fig. 2
Treatment and clinical outcomes in patients with ovarian strumal carcinoid. a Surgical options, b adjuvant therapy, c clinical outcome, d overall survival and disease-specific survival curve for patients enrolled in our study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004;90(10):1224–1228. doi: 10.1136/hrt.2004.040329. - DOI - PMC - PubMed
    1. Davis KP, Hartmann LK, Keeney GL, Shapiro H. Primary ovarian carcinoid tumors. Gynecol Oncol. 1996;61(2):259–265. doi: 10.1006/gyno.1996.0136. - DOI - PubMed
    1. Eichhorn JH, Young RH. Neuroendocrine tumors of the genital tract. Am J Clin Pathol. 2001;115(Suppl):S94–112. - PubMed
    1. Theurer S, Ingenwerth M, Herold T, Herrmann K, Schmid KW. Immunohistochemical Profile and 47-Gene Next-Generation Sequencing (NGS) Solid Tumor Panel Analysis of a Series of 13 Strumal Carcinoids. Endocr Pathol. 2020;31(2):101–107. doi: 10.1007/s12022-020-09608-3. - DOI - PMC - PubMed
    1. Chai W, Zhang W, Zhou L, Sun X, Jia G. Strumal carcinoid tumor of the ovary: A rare case report. Medicine (Baltimore) 2019;98(48):e18009. doi: 10.1097/MD.0000000000018009. - DOI - PMC - PubMed